Sample Testing definition

Sample Testing shall bear the meaning attributed to it in Clause 4.3. “Security Deposit” shall bear the meaning attributed to it in Clause 7. “Service(s)” means the service(s) described in the PO.

Sample Testing means the analyses to be performed by each Party using the applicable Samples, as described in the Data Sharing and Sample Testing Schedule (Schedule I).

Sample Testing means the analyses to be performed by Context in accordance with the Protocol using the applicable Samples.

Sample Testing means the studies to be performed by each Party using the applicable Samples, as set forth in Appendix B.

Sample Testing means the analyses to be performed by either Party using the applicable Samples, as described in the Sample Testing Schedule. "Sample Testing Results" means those results arising from the Sample Testing which are to be shared between Lilly and Sponsor, as set forth in the Sample Testing Schedule. "Sample Testing Schedule" means the schedule attached hereto as Appendix B. "Specifications" means, with respect to a given Compound, the set of requirements for such Compound as set forth in the Quality Agreement. "Sponsor" has the meaning set forth in the preamble. "Sponsor Class Compound" means any one or more bi- or multi- specific molecule that agonizes CD137 (4-1BB). "Sponsor Compound" means cinrebafusp alfa (PRS-343), a bivalent, bispecific fusion protein targeting CD137 (4-1BB) and HER2 excluding, however, any biosimilar of PRS-343 other than a biosimilar owned or controlled by Sponsor or its Affiliates. CONFIDENTIAL Pieris Study PRS‐343‐PCS_09_20 and Lilly’ I4T-NS-I025 Page 5 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because the information (I) is not material and (II) would be competitively harmful if publicly disclosed.

Sample Testing means the analyses to be performed by each Party using the applicable Samples, as described in the Sample Testing Schedule. 1.77. “Sample Testing Results” means those data and results arising from the Sample Testing performed by or on behalf of a Party. 1.78. “Sample Testing Schedule” means the schedule attached hereto as Schedule II. 1.79. “Specifications” means the requirements to which the MSD Compound and the Novocure Device must conform for use in the Study. The Specifications for the MSD Compound will be set forth in the certificate of analysis accompanying each batch of MSD Compound supplied for use in the Study and the Specifications for the Novocure Device shall be set forth in Schedule III.

Sample Testing means the analyses that may be performed by GSK using the applicable Samples, as permitted in accordance with this Agreement, including Bioanalytical Testing and Biomarker Testing.

Sample Testing means the analyses that may be performed by GSK using the applicable Samples, as permitted in accordance with this Agreement, including Bioanalytical Testing and Biomarker Testing. 1.108 “Sample Testing Results” means those data and results arising from the Sample Testing. 1.109 “Second Party” has the meaning set forth in Section 13.15(b). 1.110 “Segregate” means [***]. 1.111 “Specifications” means, with respect to a given Compound, the specifications for testing, release and stability of such Compound, as set forth in the applicable Regulatory Documentation for such Compound. 1.112 “SpringWorks” has the meaning set forth in the preamble. 1.113 “SpringWorks Background Intellectual Property” means any Intellectual Property Rights owned or controlled by SpringWorks or an Affiliate of SpringWorks that (a) exist as of the Original Effective Date or (b) arise outside of (i.e., is not made or conceived in or through) the conduct of activities under this Agreement (including, for the avoidance of doubt, activities conducted under the Original Agreement) or without the use of or reliance upon Clinical Data, the Confidential Information solely owned or controlled by GSK, or the GSK BCMA Products. 1.114 “SpringWorks Compound” means Nirogacestat or any polymorphs, salts or derivatives thereof controlled by SpringWorks. 1.115 “SpringWorks Invention” has the meaning set forth in Section 17.3. 1.116 “SpringWorks IPR” has the meaning set forth in Section 17.3. 1.117 “SpringWorks Regulatory Documentation” means any Regulatory Documentation pertaining to the SpringWorks Compound that exists as of the Original Effective Date or that is created other than in connection with this Agreement. For the avoidance of doubt, SpringWorks Regulatory Documentation does not include Study Regulatory Documentation. 1.118 “SpringWorks-Related Compound” means a compound that has the same Mechanism of Action as the SpringWorks Compound. 1.119 “Standard Contractual Clauses” means: (a) in relation to transfers of Personal Data subject to the GDPR, the standard contractual clauses for the transfer of Personal Data to third countries set out in Commission Decision 2021/914 of 4 June 2021, specifically

Sample Testing means the analyses to be performed by each Party using the applicable Samples, as described in the Sample Testing Schedule. [***] = Certain confidential information contained in this document, marked by brackets, is omitted because it is not material and would be competitively harmful if publicly disclosed.